The behavioural deficits and neurodegeneration that are observed in late-onset Alzheimer's disease are linked to high levels of amyloid-β (Aβ) in the brain, which result from a failure of Aβ clearance mechanisms. Here, the authors treated mice exhibiting Aβ-associated behavioural deficits and pathology with the retinoid X receptor (RXR) agonist bexarotene. RXR activation induces the expression of apolipoprotein E, which facilitates Aβ removal from the brain. Bexarotene treatment rapidly lowered soluble and insoluble levels of brain Aβ and improved cognitive, behavioural and olfactory deficits, indicating that RXR agonists may be useful in the treatment of Alzheimer's disease.
ORIGINAL RESEARCH PAPER
Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 9 Feb 2012 (doi:10.1126/science.1217697)
Rights and permissions
About this article
Cite this article
Yates, D. Clearing away Alzheimer's disease. Nat Rev Neurosci 13, 221 (2012). https://doi.org/10.1038/nrn3218
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrn3218